AZN vs. HLN: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at AZN and HLN, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.
Company Overview
AZN dominates in value with a market cap of 432.07 billion USD, eclipsing HLN’s 50.06 billion USD by roughly 8.63×.
With betas of 0.18 for AZN and 0.20 for HLN, both show similar volatility profiles relative to the overall market.
AZN and HLN are both ADRs—easy access for U.S. investors to foreign shares without dealing with overseas exchanges.
| Symbol | AZN | HLN |
|---|---|---|
| Company Name | AstraZeneca PLC | Haleon plc |
| Country | GB | GB |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - Specialty & Generic |
| CEO | Mr. Pascal Claude Roland Soriot D.V.M., M.B.A. | Mr. Brian James McNamara |
| Price | 69.68 USD | 11.1 USD |
| Market Cap | 432.07 billion USD | 50.06 billion USD |
| Beta | 0.18 | 0.20 |
| Exchange | NASDAQ | NYSE |
| IPO Date | May 12, 1993 | July 25, 2022 |
| ADR | Yes | Yes |
Performance Comparison
This chart compares the performance of AZN and HLN over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Hover over the lines to see the investment’s value and total return (%) at specific dates.
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
The section examines key financial ratios to assess the valuation of AZN and HLN based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.
- HLN shows a negative forward PEG of -0.26, signaling expected earnings contraction, while AZN at 2.50 maintains analysts’ projections for stable or improved profits.
| Symbol | AZN | HLN |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 27.80 | 26.08 |
| Forward PEG Ratio (TTM) | 2.50 | -0.26 |
| Price-to-Sales Ratio (P/S, TTM) | 3.93 | 3.31 |
| Price-to-Book Ratio (P/B, TTM) | 5.26 | 2.33 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 22.33 | 0.00 |
| EV-to-EBITDA (TTM) | 13.68 | 19.43 |
| EV-to-Sales (TTM) | 4.41 | 4.01 |
| EV-to-Free Cash Flow (TTM) | 25.07 | 0.00 |
Dividend Comparison
Both AZN and HLN offer similar dividend yields (1.39% vs. 1.60%), indicating comparable approaches to balancing income and growth.
| Symbol | AZN | HLN |
|---|---|---|
| Dividend Yield (TTM) | 1.39% | 1.60% |
Financial Strength Metrics Comparison
This section dives into the financial resilience of AZN and HLN, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.
- With current ratios of 0.90 and 0.98, both AZN and HLN have less current assets than short-term liabilities, which could strain their working capital and force reliance on additional financing.
- Both AZN (quick ratio 0.70) and HLN (quick ratio 0.78) fall below 0.8, meaning their most liquid assets—excluding inventory—aren’t enough to meet short-term obligations. This could force them to rely on receivables, inventory turn, or external financing.
| Symbol | AZN | HLN |
|---|---|---|
| Current Ratio (TTM) | 0.90 | 0.98 |
| Quick Ratio (TTM) | 0.70 | 0.78 |
| Debt-to-Equity Ratio (TTM) | 0.77 | 0.62 |
| Debt-to-Assets Ratio (TTM) | 0.30 | 0.29 |
| Interest Coverage Ratio (TTM) | 7.95 | 5.60 |